Cargando…

Response to trametinib treatment in progressive pediatric low-grade glioma patients

INTRODUCTION: A hallmark of pediatric low-grade glioma (pLGG) is aberrant signaling of the mitogen activated protein kinase (MAPK) pathway. Hence, inhibition of MAPK signaling using small molecule inhibitors such as MEK inhibitors (MEKi) may be a promising strategy. METHODS: In this multi-center ret...

Descripción completa

Detalles Bibliográficos
Autores principales:	Selt, Florian, van Tilburg, Cornelis M., Bison, Brigitte, Sievers, Philipp, Harting, Inga, Ecker, Jonas, Pajtler, Kristian W., Sahm, Felix, Bahr, Annabelle, Simon, Michèle, Jones, David T. W., Well, Lennart, Mautner, Victor-Felix, Capper, David, Hernáiz Driever, Pablo, Gnekow, Astrid, Pfister, Stefan M., Witt, Olaf, Milde, Till
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609413/ https://www.ncbi.nlm.nih.gov/pubmed/33026636 http://dx.doi.org/10.1007/s11060-020-03640-3

Ejemplares similares

EPCT-06. PRECISION ONCOLOGY IN THE PEDIATRIC TARGETED THERAPY 2.0 PROGRAM
por: Ecker, Jonas, et al.
Publicado: (2021)

LGG-14. LOGGIC (Low Grade Glioma in Children) Core BioClinical Data Bank: Establishment and added clinical value of an international molecular diagnostic registry for pediatric low-grade glioma patients
por: Hardin, Emily C, et al.
Publicado: (2022)

LGG-03. EXPLORING THE SIGNALING NETWORK INVOLVED IN MAPK PATHWAY INHIBITION BY THE MEK INHIBITOR TRAMETINIB IN BRAF-FUSION-DRIVEN PEDIATRIC PILOCYTIC ASTROCYTOMA
por: Sigaud, Romain, et al.
Publicado: (2023)

LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma
por: Sigaud, Romain, et al.
Publicado: (2022)

Natural History of Pediatric Low-Grade Glioma Disease - First Multi-State Model Analysis
por: Goebel, Anna-Maria, et al.
Publicado: (2019)

LGG-26. Predicting MAPK inhibitor sensitivity in pediatric low-grade gliomas with novel gene expression-derived signatures
por: Sigaud, Romain, et al.
Publicado: (2022)

LGG-02. DRUG-CLASS SPECIFIC GENE-BASED MAPK SENSITIVITY SCORES (MSS) PREDICT SENSITIVITY TO MAPK INHIBITORS AND IDENTIFY IMMUNE INFILTRATION AS PUTATIVE TARGET IN PEDIATRIC LOW-GRADE GLIOMAS
por: Sigaud, Romain, et al.
Publicado: (2023)

LGG-11. Analysis of neurosurgical complications in pediatric supratentorial midline low-grade glioma – results from the German LGG studies
por: Weiß, Sarah, et al.
Publicado: (2022)

MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas
por: Sigaud, Romain, et al.
Publicado: (2023)

LGG-11. BH3-MIMETICS TARGETING BCL-XL SELECTIVELY IMPACT THE SENESCENT COMPARTMENT OF PILOCYTIC ASTROCYTOMA
por: Selt, Florian, et al.
Publicado: (2021)

GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types
por: Sievers, Philipp, et al.
Publicado: (2021)

Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing
por: Selt, Florian, et al.
Publicado: (2016)

MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS
por: Mynarek, Martin, et al.
Publicado: (2020)

EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES GLI2 AS AN ONCOGENE OF C11orf95 FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA
por: Zheng, Tuyu, et al.
Publicado: (2020)

PATH-04. AN ENHANCED AI-DRIVEN PLATFORM FOR PRECISION MOLECULAR BRAIN TUMOR DIANOSTICS
por: Sill, Martin, et al.
Publicado: (2020)

Mutation specific antibodies: tool or dinosaur?
por: von Deimling, Andreas, et al.
Publicado: (2012)

MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation
por: Kolodziejczak, Anna, et al.
Publicado: (2022)

Long-term cognitive deficits in pediatric low-grade glioma (LGG) survivors reflect pretreatment conditions—report from the German LGG studies
por: Traunwieser, Thomas, et al.
Publicado: (2020)

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies
por: van Tilburg, Cornelis M., et al.
Publicado: (2020)

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
por: Valinciute, Gintvile, et al.
Publicado: (2023)

Clinical characterization of children and adolescents with NF1 microdeletions
por: Kehrer-Sawatzki, Hildegard, et al.
Publicado: (2020)

LGG-14. MULTI-OMIC ANALYSIS OF MAPK ACTIVATION IN PEDIATRIC PILOCYTIC ASTROCYTOMA
por: Sigaud, Romain, et al.
Publicado: (2020)

Management of pineal region tumors in a pediatric case series
por: Schulz, Matthias, et al.
Publicado: (2020)

LGG-17. SYNERGISTIC ACTIVITY OF MAPK INHIBITOR CLASSES REVEALED BY A NOVEL CELL-BASED MAPK ACTIVITY PEDIATRIC LOW-GRADE GLIOMA ASSAY
por: Usta, Diren, et al.
Publicado: (2020)

Author Correction: Phenotyping spinal abnormalities in patients with Neurofibromatosis type 1 using whole-body MRI
por: Well, Lennart, et al.
Publicado: (2021)

Phenotyping spinal abnormalities in patients with Neurofibromatosis type 1 using whole-body MRI
por: Well, Lennart, et al.
Publicado: (2021)

Genotype-phenotype correlation in neurofibromatosis type-1: NF1 whole gene deletions lead to high tumor-burden and increased tumor-growth
por: Well, Lennart, et al.
Publicado: (2021)

Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts
por: Mynarek, Martin, et al.
Publicado: (2022)

PATH-11. PROSPECTIVE (EPI-)GENETIC CLASSIFICATION OF > 1,000 PEDIATRIC CNS TUMORS—THE MNP 2.0 STUDY
por: Sturm, Dominik, et al.
Publicado: (2020)

Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience
por: Capper, David, et al.
Publicado: (2018)

Structural alteration of lung parenchyma in patients with NF1: a phenotyping study using multidetector computed tomography (MDCT)
por: Avanesov, Maxim, et al.
Publicado: (2021)

The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma
por: Ghasemi, David R., et al.
Publicado: (2022)

EPEN-09. IMPACT OF MOLECULAR SUBGROUP ON OUTCOME FOR INFANTS <12 MONTHS WITH INTRACRANIAL EPENDYMOMA - GERMAN EXPERIENCE FROM HIT2000, INTERIM-2000-REGISTRY AND I-HIT-MED REGISTRY
por: Obrecht, Denise, et al.
Publicado: (2020)

EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA
por: Valinciute, Gintvile, et al.
Publicado: (2021)

Atypical NMDA receptor expression in a diffuse astrocytoma, MYB- or MYBL1-altered as a trigger for autoimmune encephalitis
por: Nikolaus, Marc, et al.
Publicado: (2022)

Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies
por: Adolph, Jonas E., et al.
Publicado: (2021)

EPEN-03. ZFTA/C11ORF95 FUSIONS DRIVE SUPRATENTORIAL EPENDYMOMA VIA SHARED ONCOGENIC MECHANISMS
por: Zheng, Tuyu, et al.
Publicado: (2021)

HGG-23. DECIPHERING THE RELATIONSHIP OF MICROSATELLITE-INSTABILITY AND MUTATIONAL BURDEN IN HIGH-GRADE GLIOMA PATIENTS WITH CONSTITUTIONALLY IMPAIRED DNA DAMAGE RESPONSE
por: Blattner-Johnson, Mirjam, et al.
Publicado: (2023)

PATH-26. RNA SEQUENCING OF FORMALIN-FIXED PARAFFIN-EMBEDDED SPECIMENS IN DIAGNOSTIC ROUTINE IDENTIFIES CLINICALLY RELEVANT GENE FUSIONS
por: Stichel, Damian, et al.
Publicado: (2020)

LGG-16. NOVEL COMBINATION THERAPIES FOR PEDIATRIC LOW-GRADE GLIOMA AND CHARACTERIZATION OF THE UNDERLYING CELL DEATH MECHANISMS
por: Zeiser, Constantia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cjpnnhtuntf6ie68q5dtjm45cd